KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Income from Continuing Operations: 2011-2025

Historic Income from Continuing Operations for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $25.7 million.

  • Travere Therapeutics' Income from Continuing Operations rose 146.95% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 74.63%. This contributed to the annual value of -$320.6 million for FY2024, which is 14.80% up from last year.
  • As of Q3 2025, Travere Therapeutics' Income from Continuing Operations stood at $25.7 million, which was up 301.54% from -$12.8 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Income from Continuing Operations peaked at $25.7 million during Q3 2025, and registered a low of -$136.0 million during Q1 2024.
  • Over the past 3 years, Travere Therapeutics' median Income from Continuing Operations value was -$69.7 million (recorded in 2024), while the average stood at -$65.9 million.
  • As far as peak fluctuations go, Travere Therapeutics' Income from Continuing Operations slumped by 6,574.40% in 2021, and later soared by 146.95% in 2025.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Income from Continuing Operations stood at -$88.8 million in 2021, then increased by 3.53% to -$85.6 million in 2022, then fell by 3.46% to -$88.6 million in 2023, then soared by 31.97% to -$60.3 million in 2024, then skyrocketed by 146.95% to $25.7 million in 2025.
  • Its Income from Continuing Operations was $25.7 million in Q3 2025, compared to -$12.8 million in Q2 2025 and -$41.2 million in Q1 2025.